What InVivo Biosystems does

InVivo Biosystems is a privately held contract research organization (CRO) founded in 2011 and headquartered in Eugene, Oregon, that provides genome editing and preclinical research services using whole-organism models—primarily zebrafish and C. elegans. The company targets pharmaceutical and biotechnology companies, academic research institutions, and nutraceutical firms, positioning its services as faster, more cost-effective alternatives to traditional rodent-based preclinical workflows. Since inception, InVivo Biosystems has served 400+ clients, delivered 600+ studies, and produced 3,000+ C. elegans transgenic lines, with stated outcomes of 79% treatment correlation to traditional PDX oncology benchmarks and up to 98% reduction in validation study timelines.

The company's core offering is the RapidGen™ Platform, an AI-augmented in vivo discovery system that integrates conserved biology models, advanced genetics, multi-omics readouts, and computer-vision-based behavioral phenotyping to produce decision-ready data packages. Proprietary technologies include MIC-Drop™ (a multiplexed CRISPR platform exclusively licensed from the University of Utah, enabling simultaneous gene editing in F0 generation with non-linear labor scaling), the ZTX® Oncology Platform (zebrafish tumor xenograft for cancer drug efficacy testing, co-developed with BioReperia), and the FishCam Smart Rack (an AI-powered continuous zebrafish colony monitoring system funded through NIH SBIR grants). The intellectual property portfolio includes 10+ issued patents covering gene editing methods, whole-organism phenotyping, and automation.

InVivo Biosystems operates a fee-for-service revenue model with project-based contracts covering CRISPR gene editing (knock-in, knockout, transgenic services), preclinical compound efficacy and toxicity testing, disease modeling across neurological and metabolic indications, and genomic services including strain validation and storage. Pricing is unit-based, with gene editing projects ranging from $440 (Inject Express) to $3,812+ (Full Build CRISPR knock-in), with 50/50 milestone payment structures. The company pursues a consultative, partnership-driven sales motion targeting enterprise clients through direct engagement. Cumulative funding across equity rounds and grants totals approximately $12.8 million, including a $3M seed round led by Rogue Venture Partners in January 2024 and $2.8M in NIH grant funding, supplemented by Phase II SBIR support for FishCam development.

Name

InVivo Biosystems

Legal name

InVivo Biosystems

Website

https://invivobiosystems.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

InVivo Biosystems is an Eugene, Oregon-based contract research organization providing CRISPR gene editing and preclinical research services using zebrafish and C. elegans whole-organism models for pharmaceutical, biotech, academic, and nutraceutical clients.

Ownership category

akta.pro rank

Product category

Preclinical Contract Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq) (HLAAAIAG)

Keywords

• Preclinical research services
• CRISPR gene editing
• Zebrafish disease models
• Contract research organization
• In vivo drug discovery

Headquarters

HQ city

Eugene

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Contract Research Services (CRO): Fee-for-service preclinical research services including compound efficacy testing, toxicity testing, disease modeling, and genomic services. Projects are custom-designed with clients and delivered with detailed reports and data packages. Revenue generated through project-based contracts with pharmaceutical, biotech, and nutraceutical companies.
2. Gene Editing Services: CRISPR-based gene editing services for zebrafish and C. elegans models including knock-in, knockout, and transgenic services. Offered as full build, candidate lines, or custom injection mix packages. Revenue from one-time project fees.
3. NIH SBIR Grants: Non-dilutive funding from NIH Small Business Innovation Research grants supporting development of AI-powered technologies like FishCam Smart Rack for zebrafish health monitoring.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

InVivo Biosystems operates as a contract research organization providing preclinical drug discovery and genome editing services using CRISPR-edited zebrafish and C. elegans whole-organism models. The company delivers fee-for-service compound efficacy testing, toxicity testing, disease modeling, and gene editing (knock-in, knockout, transgenic) for pharmaceutical, biotech, nutraceutical, and academic clients, supported by the proprietary RapidGen™ AI-powered platform and MIC-Drop™ multiplexed CRISPR technology.

Product overview

InVivo Biosystems operates as a technology and services platform focused on therapeutic discovery using whole-organism models (zebrafish and C. elegans). The core offering is the RapidGen Platform, an AI-powered in vivo discovery system that generates scalable data from conserved biology models. Supporting this platform are specialized technology offerings including MIC-Drop for multiplexed CRISPR gene editing and the ZTX Oncology Platform for cancer drug testing. The company provides comprehensive service offerings across gene editing (CRISPR knockout/knock-in, MosSCI, Tol2 transgenesis), disease modeling (epilepsy, Parkinson's, Alzheimer's, cancer, ocular diseases), preclinical compound testing (toxicity, efficacy, vitality studies), and genomic services (strain validation, maintenance, injection services). The portfolio is unified through the RapidGen Platform which integrates AI-driven data analysis with whole-organism phenotyping capabilities.

Differentiator

Problem solved

Functional benefit

Brands

• RapidGen™ Platform: AI-powered platform that generates scalable, decision-ready data from whole-organism models (zebrafish and C. elegans) for therapeutic discovery.
• MIC-Drop™
• ZTX® Oncology Platform
• FishCam Smart Rack

Products and services

• RapidGen Platform

Quantifiable outcome

• 79% treatment correlation to traditional PDX therapeutic outcomes
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability6 records

Feature4 records

Partnerships

Two partnerships are on record, tiered core technology partner and platform partner.

• University of Utahcore technology partnerOEM/ Whitelabel/ Licensing Partner · 3 January 2024Granted InVivo Biosystems an exclusive license for the MIC-Drop CRISPR technology. This licensing agreement provides InVivo with proprietary rights to their multiplexed gene editing platform.
• BioReperiaplatform partnerTechnology or IntegrationStrategic partnership for the ZTX® Oncology Platform, combining BioReperia's tumor xenograft capabilities with InVivo Biosystems' zebrafish platform for accelerated cancer drug discovery.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• ZeClinics: Specialty CRO focused on zebrafish-based preclinical drug discovery and toxicity assessment; directly competes with InVivo Biosystems for pharma/biotech zebrafish toxicology and efficacy screening contracts.
• Crown Bioscience: Preclinical CRO offering in vivo oncology and translational research services including zebrafish xenograft platforms (via the ZTX-like capabilities); directly comparable to InVivo's ZTX Oncology Platform offerings.

Broad incumbents

• Charles River Laboratories: Largest global preclinical CRO offering discovery, safety assessment, and manufacturing services across multiple model organisms; broad incumbent that competes for early-discovery and toxicology spend that InVivo targets.
• Evotec: Global CRO/CDMO with deep preclinical discovery services including in vivo pharmacology and disease modeling; competes for outsourced preclinical budgets across pharma/biotech.
• Inotiv: Preclinical CRO and research models provider with rodent-centric discovery and safety assessment services; competes for the same pharma R&D budgets that InVivo addresses via alternative model organisms.
• Fortrea (former Labcorp Drug Development/Covance): Large-scale preclinical and clinical CRO spun out of Labcorp; competes for outsourced early-discovery and toxicology work with full GLP infrastructure that InVivo currently lacks.
• Wuxi AppTec: Global CRO/CDMO with extensive preclinical discovery and safety assessment capacity; serves large pharma with integrated discovery-to-manufacturing workflows competing for outsourced preclinical studies.

Emerging players

• PsychoGenics: Preclinical CRO specializing in CNS/neuro disease modeling and behavioral phenotyping; overlaps with InVivo's neurotoxicity and neurodegenerative disease model services (Alzheimer's, Parkinson's, epilepsy).
• Bionova Scientific: Preclinical services provider with focus on biologics manufacturing and related discovery support; partial overlap with InVivo's preclinical testing workflows for biotech clients.

Others

• Knudra Transgenics: Predecessor entity acquired by InVivo Biosystems in 2017 for C. elegans transgenesis capabilities; historically a comparable niche model-organism service provider before integration.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/invivobiosystems
• Xx.com/invivobiosystem
• Facebookfacebook.com/invivobiosystems

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds8 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InVivo Biosystems